NeoGenomics - Public Comps and Valuation Multiples

NeoGenomics Overview

About NeoGenomics

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Founded

1998

HQ

Employees

2.2K+

Website

neogenomics.com

Sectors

Laboratory Services
Medical Imaging & Diagnostics
BioTech
HealthTech

Financials

LTM Revenue $711M

LTM EBITDA $41.1M

EV

$1.5B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

NeoGenomics Financials

As of September 2025, NeoGenomics reported last 12-month revenue of $711M and EBITDA of $41.1M.

In the same period, NeoGenomics generated $315M in LTM gross profit and -$107M in net income.

See NeoGenomics valuation multiples based on analyst estimates

NeoGenomics P&L

In the most recent fiscal year, NeoGenomics reported revenue of $661M and EBITDA of -$1.5M.

NeoGenomics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See NeoGenomics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$711M	XXX	$661M	XXX	XXX	XXX
Gross Profit	$315M	XXX	$290M	XXX	XXX	XXX
Gross Margin	44%	XXX	44%	XXX	XXX	XXX
EBITDA	$41.1M	XXX	-$1.5M	XXX	XXX	XXX
EBITDA Margin	6%	XXX	0%	XXX	XXX	XXX
EBIT	-$115M	XXX	-$85.4M	XXX	XXX	XXX
EBIT Margin	-16%	XXX	-13%	XXX	XXX	XXX
Net Profit	-$107M	XXX	-$78.7M	XXX	XXX	XXX
Net Margin	-15%	XXX	-12%	XXX	XXX	XXX
Net Debt	XXX	XXX	$174M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for NeoGenomics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $711M. EBITDA for the last twelve months was $41.1M. In the most recent fiscal year, NeoGenomics achieved $661M in revenue and -$1.5M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$711M	Analyst estimates available to subscribers	$661M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$315M	Analyst estimates available to subscribers	$290M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	44.3% gross margin	Analyst estimates available to subscribers	43.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$41.1M	Analyst estimates available to subscribers	-$1.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	5.8% EBITDA margin	Analyst estimates available to subscribers	-0.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$115M	Analyst estimates available to subscribers	-$85.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-16.2% EBIT margin	Analyst estimates available to subscribers	-12.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$107M	Analyst estimates available to subscribers	-$78.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-15.1% net profit margin	Analyst estimates available to subscribers	-11.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$174M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for NeoGenomics

This financial data table provides comprehensive performance metrics for NeoGenomics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

NeoGenomics generated $711M in revenue over the last twelve months.
The company achieved $41.1M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $315M.
Net income over the last twelve months reached -$107M.

Fiscal Year Performance

In the most recent fiscal year, NeoGenomics reported $661M in total revenue.
Fiscal year EBITDA was -$1.5M.
The company maintained a gross profit margin of 43.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was -0.2%.
Net profit margin reached -11.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for NeoGenomics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

NeoGenomics Stock Performance

NeoGenomics has current market cap of $1.3B, and EV of $1.5B.

Market Cap Evolution

NeoGenomics Stock Data

As of October 17, 2025, NeoGenomics's stock price is $10.

See NeoGenomics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.5B	$1.3B	XXX	XXX	XXX	XXX	$0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

NeoGenomics Valuation Multiples

NeoGenomics's trades at 2.3x EV/Revenue multiple, and -1023.4x EV/EBITDA.

See valuation multiples for NeoGenomics and 15K+ public comps

NeoGenomics Financial Valuation Multiples

As of October 17, 2025, NeoGenomics has market cap of $1.3B and EV of $1.5B.

Equity research analysts estimate NeoGenomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

NeoGenomics has a P/E ratio of -12.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.3B	XXX	$1.3B	XXX	XXX	XXX
EV (current)	$1.5B	XXX	$1.5B	XXX	XXX	XXX
EV/Revenue	2.2x	XXX	2.3x	XXX	XXX	XXX
EV/EBITDA	37.6x	XXX	-1023.4x	XXX	XXX	XXX
EV/EBIT	-13.5x	XXX	-18.1x	XXX	XXX	XXX
EV/Gross Profit	4.9x	XXX	n/a	XXX	XXX	XXX
P/E	-12.1x	XXX	-16.5x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-45.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get NeoGenomics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

NeoGenomics Margins & Growth Rates

NeoGenomics's last 12 month revenue growth is 10%

NeoGenomics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

NeoGenomics's rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

NeoGenomics's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for NeoGenomics and other 15K+ public comps

NeoGenomics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	10%	XXX	10%	XXX	XXX	XXX
EBITDA Margin	6%	XXX	0%	XXX	XXX	XXX
EBITDA Growth	29%	XXX	n/a	XXX	XXX	XXX
Rule of 40	7%	XXX	10%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	31%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	57%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial